Acquirer · Corporate
UCB
2$3.35bn$2.2bn0
Photo: J.N. Eskra / Wikimedia Commons, CC BY-SA 4.0UCB agrees to buy Candid Therapeutics for $2 billion upfront in deal worth up to $2.2 billion
The sale replaced Candid's planned Nasdaq listing through a reverse merger with Rallybio, which Candid called off a day earlier, triggering a $50 million termination fee.
$2.2bn$370mSeries ACorporate
